ClinicalTrials.gg
CompletedNCT02259803Updated Oct 9, 2014

Relative Bioavailability of Telmisartan/Amlodipine Fixed-dose Combination Compared to Its Mono-components in Healthy Male Volunteers

A Phase 1 interventional study of Telmisartan/amlodipine fixed-dose combination (FDC) tablet and Telmisartan in Healthy, sponsored by Boehringer Ingelheim. Completed. Open to male participants aged 20 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-09.

Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
20 Years to 35 Years
Sex
Male
01

Study summary

Study to investigate the relative bioavailability of fixed-dose combination tablet vs.

mono-components of telmisartan and amlodipine

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 35 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy males according to the following criteria:

    Based upon a complete medical history, including the physical examination, vital signs (blood pressure, pulse rate and body temperature), 12-lead , clinical laboratory tests, no finding of clinical relevance, no evidence of a concomitant disease

  2. Age ≥20 and Age ≤35 years
  3. Body weight ≥50 kg
  4. ≥17.6 and BMI ≤26.4 kg/m2 (Body Mass Index)
  5. Signed and dated written prior to admission to the study in accordance with Good Clinical Practice

Exclusion criteria

Exclusion Criteria:

  1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
  2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
  3. Chronic or relevant acute infections
  4. Any clinical relevant findings of the laboratory test deviating from normal
  5. Positive result for antigen, anti virus anti bodies, syphilitic test or test
  6. Surgery of gastrointestinal tract (except appendectomy)
  7. History of relevant orthostatic hypotension (mean standing systolic blood pressure (SBP) varies by ≥20 mmHg from mean supine SBP or mean standing diastolic blood pressure (DBP) varies by ≥10 mmHg from mean supine DBP), fainting spells or blackouts
  8. History of hepatic dysfunction (e.g. biliary cirrhosis, cholestasis)
  9. History of serious renal dysfunction
  10. History of bilateral renal artery stenosis or renal artery stenosis in a solitary kidney
  11. History of cerebrovascular disorder
  12. History of hyperkalemia
  13. Known to any component of the formulation, or to any other angiotensin II receptor blockers, angiotensin converting enzyme or dihydropyridine
  14. Intake of drugs with a long half-life (≥24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial
  15. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 7 days prior to administration or during the trial
  16. Participation in another trial with an drug within 4 months or 6 half-lives of the investigational drug prior to administration
  17. Smoker (≥20 cigarettes/day)
  18. Alcohol abuse (60 g or more ethanol/day: ex. 3 middle-sized bottles of beer, 3 gous (equivalent to 540 mL) of sake)
  19. Drug abuse
  20. Blood donation (more than 100 mL within 4 weeks prior to administration or during the trial)
  21. Excessive physical activities (within 1 week prior to administration or during the trial)
  22. Intake of alcohol within 2 days prior to administration
  23. Inability to comply with dietary regimen of study centre
  24. Intake of any drugs/supplements with ingredient of hypericum perforatum or citrus fruits (e.g. grapefruits, Sevilla orange) within 5 days prior to administration
  25. Inability to refrain from smoking on trial days
  26. Any other volunteers whom, the principal investigator or sub investigator would not allow to participate in this study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Telmisartan/amlodipine fixed-dose combination

    Drug: Telmisartan/amlodipine fixed-dose combination (FDC) tablet

  • Active comparator
    Telmisartan and amlodipine mono-components

    Drug: Telmisartan · Drug: Amlodipine

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point (AUC0-tz)

    Time frame: up to 144 hours after administration of study drug

  2. Maximum measured concentration of the analyte in plasma (Cmax)

    Time frame: up to 144 hours after administration of study drug

Secondary outcomes

  1. Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞)

    Time frame: up to 144 hours after administration of study drug

  2. Time from administration to the maximum concentration of the analyte in plasma (tmax)

    Time frame: up to 144 hours after administration of study drug

  3. Terminal rate constant of the analyte in plasma (λz)

    Time frame: up to 144 hours after administration of study drug

  4. Terminal rate constant of the analyte in plasma (t1/2)

    Time frame: up to 144 hours after administration of study drug

  5. Mean residence time of the analyte in the body after po administration (MRTpo)

    Time frame: up to 144 hours after administration of study drug

  6. Number of subjects with adverse events

    Time frame: up to 56 days

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007 and a primary completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2014
First posted
Oct 9, 2014
Start
Oct 2007
Primary completionActual
Nov 2007
Last update
Oct 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02259803
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Oct 2007
Primary completion
Nov 2007
Last update
Oct 9, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion